Abu Dhabi’s Department of Health has signed a Memorandum of Understanding (MoU) with AstraZeneca (LSE: AZN) to establish a world-class Rare Diseases Centre of E 7 June 2024
Moderna (Nasdaq: MRNA) has announced that the US Food and Drug Administration has selected mRNA-3705 for the Support for Clinical Trials Advancing Rare Disease 6 June 2024
US biotech major Gilead Sciences has announced two-year interim results from the ongoing ASSURE study of investigational seladelpar for the treatment of primary 5 June 2024
Australia’s Neuren Pharmaceuticals has announced top-line results from its Phase II trial of NNZ-2591 in children with Pitt Hopkins syndrome (PTHS). 28 May 2024
USA-based Nippon Shinyaku (TYO: 4516) subsidiary NS Pharma has published a disappointing initial analysis from an important trial of Viltepso (viltolarsen). 28 May 2024
SynaptixBio, a UK biotech that claims to be the world’s only company developing a therapy for TUBB4A-related leukodystrophies, has appointed Uwe Meya as chief m 23 May 2024
Roche’s Japan-based subsidiary Chugai has launched PiaSky for injection 340 mg (crovalimab), a pH-dependent binding humanized anti-complement (C5) monoclonal an 23 May 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.